Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MREO?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.375
Low
0.50
Averages
2.08
High
5.00
Current: 0.375
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
See More
Mereo BioPharma Faces Securities Class Action Over BMD Claims
- Lawsuit Background: Mereo BioPharma Group plc is facing a securities class action for allegedly misrepresenting the relationship between bone mineral density (BMD) improvements and fracture reduction, with a court deadline of April 6, 2026, for lead plaintiff applications, highlighting a strong demand for transparency from investors.
- Management Accountability: The lawsuit claims that management failed to disclose the lack of control group comparisons in Phase 2 data while touting a 67% reduction in annualized fracture rates, which could undermine investor confidence due to insufficient evidence of causation.
- Industry Impact: This case underscores the fundamental question of whether BMD improvements can serve as a reliable surrogate endpoint for fracture reduction; while the company has achieved some progress in BMD, it has not met market expectations for clinically meaningful fracture reductions, potentially affecting future financing and market performance.
- Legal Support: Levi & Korsinsky, LLP, recognized as a leader in shareholder rights litigation, has been ranked in ISS Securities Class Action Services' Top 50 for seven consecutive years, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Mereo BioPharma Group plc, alleging violations of federal securities laws on behalf of all investors who purchased Mereo securities between June 5, 2023, and December 26, 2025.
- False Statements Allegations: The complaint claims that throughout the class period, the defendants made overly positive statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, misleading investors about the company's true condition.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares between June 5, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status for recovery.
- False Statements Allegations: The complaint alleges that Mereo provided overly positive statements about the Phase 3 ORBIT and COSMIC programs while concealing significant adverse facts, misleading investors about the trials' failure to meet primary endpoints.
- Stock Price Collapse: Following a press release on December 29, 2025, stating that neither study achieved statistical significance, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29, representing a decline of over 87.7%.
- Claim Deadline: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress to ensure their rights are protected.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc must note that the deadline to apply as lead plaintiff is April 6, 2026, covering the period from June 5, 2023, to December 26, 2025, and failure to apply may result in loss of claims.
- Lawsuit Background: The lawsuit alleges that Mereo's positive statements regarding setrusumab in its Phase 3 Orbit and COSMIC studies were misleading, as the studies failed to meet their primary endpoint of reducing clinical fracture rates, leading investors to purchase ADSs at inflated prices.
- Choosing Legal Counsel: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective representation in securities class actions.
- Investor Losses: The lawsuit claims that due to the defendants' misleading information, investors suffered damages, with the Rosen Law Firm having recovered over $438 million for investors in 2019, demonstrating its strong capabilities in securities class action litigation.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
See More
Mereo BioPharma Faces Securities Class Action Over BMD Claims
- Lawsuit Background: Mereo BioPharma Group plc is facing a securities class action for allegedly misrepresenting the relationship between bone mineral density (BMD) improvements and fracture reduction, with a court deadline of April 6, 2026, for lead plaintiff applications, highlighting a strong demand for transparency from investors.
- Management Accountability: The lawsuit claims that management failed to disclose the lack of control group comparisons in Phase 2 data while touting a 67% reduction in annualized fracture rates, which could undermine investor confidence due to insufficient evidence of causation.
- Industry Impact: This case underscores the fundamental question of whether BMD improvements can serve as a reliable surrogate endpoint for fracture reduction; while the company has achieved some progress in BMD, it has not met market expectations for clinically meaningful fracture reductions, potentially affecting future financing and market performance.
- Legal Support: Levi & Korsinsky, LLP, recognized as a leader in shareholder rights litigation, has been ranked in ISS Securities Class Action Services' Top 50 for seven consecutive years, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Mereo BioPharma Group plc, alleging violations of federal securities laws on behalf of all investors who purchased Mereo securities between June 5, 2023, and December 26, 2025.
- False Statements Allegations: The complaint claims that throughout the class period, the defendants made overly positive statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, misleading investors about the company's true condition.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares between June 5, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status for recovery.
- False Statements Allegations: The complaint alleges that Mereo provided overly positive statements about the Phase 3 ORBIT and COSMIC programs while concealing significant adverse facts, misleading investors about the trials' failure to meet primary endpoints.
- Stock Price Collapse: Following a press release on December 29, 2025, stating that neither study achieved statistical significance, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29, representing a decline of over 87.7%.
- Claim Deadline: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress to ensure their rights are protected.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc must note that the deadline to apply as lead plaintiff is April 6, 2026, covering the period from June 5, 2023, to December 26, 2025, and failure to apply may result in loss of claims.
- Lawsuit Background: The lawsuit alleges that Mereo's positive statements regarding setrusumab in its Phase 3 Orbit and COSMIC studies were misleading, as the studies failed to meet their primary endpoint of reducing clinical fracture rates, leading investors to purchase ADSs at inflated prices.
- Choosing Legal Counsel: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective representation in securities class actions.
- Investor Losses: The lawsuit claims that due to the defendants' misleading information, investors suffered damages, with the Rosen Law Firm having recovered over $438 million for investors in 2019, demonstrating its strong capabilities in securities class action litigation.
See More
